Clinical trials: Meningococcal Infections, active
Meningitis, Meningococcal
Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
The purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease…
- Trial name
- NCT05087056
- Testing
- MenABCWY vaccine
- Where
- 30 sites in United States, Germany
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Splenectomy; Status
Meningococcal B Vaccine in Patients with Asplenia
Patients without a spleen (asplenia) experience an increased risk for septicaemia from encapsulated bacteria, which is associated with a high mortality rate.
- Trial name
- NCT06025487
- Testing
- Bexsero
- Where
- Austria
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Meningococcal Meningitis
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds
This is a randomized, observer-blind, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1…
- Trial name
- NCT06226714
- Testing
- MCV4, MPSV4
- Where
- 3 sites in China
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Meningococcal Meningitis
Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine
This trial adopts an open-label design combined with randomized, blinded, placebo-controlled and active-controlled design. The purpose of this trial is to evaluate the safety and immunogenicity of a Group ACYW135X Meningococcal…
- Trial name
- NCT07374510
- Testing
- high-dose Group ACYW135X Meningococcal Conjugate Vaccine, medium-dose Group ACYW135X Meningococcal Conjugate Vaccine, low-dose Group ACYW135X Meningococcal Conjugate Vaccine
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis
Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
This clinical trial is conducted in two parts. Part One employs a randomized, partially blinded, dose-escalation, partially active-controlled design. Part Two utilizes a randomized, blinded, placebo-controlled design.
- Conditions
- Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection
- Trial name
- NCT07203755
- Testing
- Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4), DTcP-Hib-MCV4, Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP)
- Where
- China
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Meningitis, Meningococcal
A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age
The purpose of this study is to assess the safety and immune responses of rMenB+OMV NZ vaccine when administered to healthy infants from 2 months in the Republic of Korea according to a 2-dose primary schedule and 1 booster dose.
- Trial name
- NCT06113198
- Testing
- rMenB+OMV NZ
- Where
- 8 sites in South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Disease; Meningococcal Meningitis
Single-center, Open-label Study: Immunogenicity and Safety Observation After Vaccination With ACYW135 Meningococcal Polysaccharide Vaccine in Junior High School Students Aged 13-15 Years
The sample size of this study is 200 participants, aiming to evaluate the protective effect after vaccination with quadrivalent meningococcal polysaccharide vaccine in the 13-15 age group, and to provide scientific evidence and…
- Trial name
- NCT07885371
- Testing
- MPSV-ACYW
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Meningococcal Infections
Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old
Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine
- Trial name
- NCT07204457
- Testing
- EG-MCV4, Menveo
- Where
- South Korea
- Volunteers
- 1,123 people, healthy volunteers welcome
- Sponsor
- EyeGene Inc.
Epidemic Meningitis, Meningococcal Vaccines
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months
The goal of this clinical trial is to evaluate the immunogenicity, safety, and immune persistence of the primary series of an investigational group ACYW135 meningococcal conjugate vaccine, as well as the immunogenicity and safety…
- Trial name
- NCT07505810
- Testing
- experimental vaccine, Active Comparator vaccine
- Where
- 2 sites in China
- Volunteers
- 880 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Meningococcal Immunization, Healthy Volunteers
Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants
This study is the first study of Sanofi's Pentavalent Meningococcal ABCYW vaccine clinical development program to be conducted in the pediatric population below 10 years of age.
- Trial name
- NCT06647407
- Testing
- Pentavalent Meningococcal ABCYW vaccine, MenACYW conjugate vaccine, Meningococcal group B vaccine
- Where
- 39 sites in Brazil, Czechia and 7 more
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Meningococcal Disease
A Study to Learn About the Safety of PENBRAYA During Pregnancy
This study is a pregnancy registry designed to learn more about the safety of the study vaccine PENBRAYA (a vaccine that protects against meningitis causing bacteria) when it is given during pregnancy or within 30 days before the…
- Trial name
- NCT07768163
- Testing
- PENBRAYA
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
Gonorrhea, Sexually Transmitted Infection
Efficacy Trial on Meningococcal B Vaccine for Preventing Gonorrhea Infections
Objectives: Efficacy of a meningococcal vaccine against Neisseria gonorrhoea (NG) infection among men who have sex with men (MSM). Design: Parallel randomised double-blind placebo-controlled trial.
- Trial name
- NCT05766904
- Testing
- 4CMenB vaccine
- Where
- Hong Kong
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Meningococcal Infection
Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)
Primary Objective: To assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women vaccinated with MenQuadfi® during pregnancy or in the 30 days preceding their Last Menstrual Period (LMP).
- Trial name
- NCT04843111
- Testing
- Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Hiv, Meningococcal Infections
Safety and Immunogenicity Following Meningococcal and Pneumococcal Immunization Among Adult People Living With HIV
MENPI is an investigator-initiated single-centre randomized controlled trial which aims to assess the efficacy and safety of meningococcal and pneumococcal vaccination in adults living with HIV receiving antiretroviral treatment.
- Conditions
- Hiv, Meningococcal Infections, Pneumococcal Infections
- Trial name
- MENPI (NCT04875819)
- Testing
- Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine, 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- Thomas Benfield
Infections, Meningococcal
Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug
Assessment of immunogenicity, reactogenicity and safety of GNG-DE in comparison with the reference drug
- Trial name
- NCT06834100
- Testing
- polysaccharide conjugated vaccine for prevention of meningococcal infection of serogroups A, C, W, Y
- Where
- 17 sites in Russia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- NPO Petrovax
Epidemic Meningitis, Meningococcal Vaccines
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years
The goal of this clinical trial is to evaluate the immunogenicity and safety of an investigational group ACYW135 meningococcal conjugate vaccine in healthy children aged 2 to 6 years.
- Trial name
- NCT07505888
- Testing
- experimental vaccine, active comparator vaccine
- Where
- China
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Neisseria Gonorrheae Infection
Efficacy Study of 4CMenB (Bexsero®) to Prevent Gonorrhoea Infection in Gay and Bisexual Men
This is a Phase 3, double-blinded, randomised placebo-controlled, multi-centred trial evaluating the efficacy of the four-component meningococcal B vaccine, 4CMenB (Bexsero®), in the prevention of Neisseria gonorrhoeae…
- Trial name
- GoGoVax (NCT04415424)
- Testing
- 4CMenB vaccine
- Where
- 7 sites in Australia
- Volunteers
- 650 people
- Sponsor
- Kirby Institute
Epidemic Meningitis, Meningococcal Vaccines
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months
The goal of this clinical trial is to evaluate the immunogenicity and safety of an investigational group ACYW135 Meningococcal conjugate vaccine in healthy children aged 12 to 23 months.
- Trial name
- NCT07505836
- Testing
- experimental vaccine, Active Comparator vaccine
- Where
- 2 sites in China
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Gonorrhea, Neisseria Gonorrhea
Metagenomic Analysis of the Pharynx in High Risk Partners
The Neisseria gonorrhoea (NG) epidemic in England is at the highest level in one hundred years of public health records. The World Health Organisation has listed NG as one of the top five bacterial infections globally because of…
- Conditions
- Gonorrhea, Neisseria Gonorrhea, Neisseria Meningitidis, Metagenomic Next Generation Sequencing
- Trial name
- NCT07671014
- Volunteers
- 100 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Meningitis, Children, Only
National Bacterial Meningitis Study in Children and Newborns
Bacterial meningitis is a major cause of morbidity and mortality in childhood. Antibiotic treatment recommendations are based on epidemiological and susceptibility data.
- Conditions
- Meningitis, Children, Only, Pneumococcal Conjugate Vaccine, Meningococcal Vaccines
- Trial name
- NCT04664569
- Where
- France
- Volunteers
- 10,000 people
- Sponsor
- Association Clinique Thérapeutique Infantile du val de Marne